{"gene":"NHLRC1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2003,"finding":"NHLRC1 (EPM2B) encodes malin, a protein containing a RING finger domain and six NHL motifs, consistent with a putative E3 ubiquitin ligase. Malin and laforin (EPM2A) colocalize to the endoplasmic reticulum, suggesting they operate in a related pathway protecting against polyglucosan accumulation.","method":"Gene identification by positional cloning; colocalization by cell imaging","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — domain-based prediction of E3 ligase activity plus colocalization; replicated in subsequent studies but original evidence is domain inference + colocalization without in vitro reconstitution","pmids":["12958597"],"is_preprint":false},{"year":2008,"finding":"NHLRC1 disease-associated missense mutations alter the subcellular localization of malin: three mutants (of six tested) targeted the nucleus, one formed perinuclear aggregates, and two showed no significant difference compared to wild-type malin, suggesting that altered subcellular localization of mutant malin is a molecular basis of Lafora disease.","method":"Expression of NHLRC1 missense mutants in cultured cells with subcellular localization analysis","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization experiment in mammalian cells with multiple mutants; single lab, no functional rescue shown","pmids":["18311786"],"is_preprint":false},{"year":2009,"finding":"The NHLRC1 missense mutation H187P impairs malin's ability to degrade laforin in vitro, directly linking this mutation to loss of malin E3 ubiquitin ligase function toward its substrate laforin.","method":"In vitro degradation assay of laforin by mutant malin (H187P) in cultured mammalian cells","journal":"Neurogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct functional assay establishing laforin as a substrate of malin's ubiquitin ligase activity, single lab single mutant","pmids":["19322595"],"is_preprint":false},{"year":2011,"finding":"Disease-associated NHLRC1 mutations (C46Y, P69A, D146N, L261P) cause failure to downregulate R5/PTG (a regulatory subunit of protein phosphatase 1 involved in glycogen synthesis) and lead to abnormal intracellular glycogen accumulation in cultured mammalian cells, demonstrating that malin regulates glycogen metabolism through control of R5/PTG levels.","method":"Expression of NHLRC1 mutants in cultured mammalian cells; measurement of R5/PTG protein levels and intracellular glycogen accumulation","journal":"Journal of molecular medicine (Berlin, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay with multiple mutants and two orthogonal readouts (R5/PTG levels + glycogen accumulation), single lab","pmids":["21505799"],"is_preprint":false},{"year":2003,"finding":"Laforin and malin interact with each other and function as a complex that regulates glycogen metabolism; loss of either protein leads to polyglucosan (Lafora body) accumulation.","method":"Genetic and cell biological evidence from patient mutations and colocalization studies; complex function inferred from genetic epistasis","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 3 / Strong — supported by multiple independent studies documenting interaction and shared pathway, but original evidence is colocalization/genetic; interaction confirmed biochemically in subsequent work described in reviews","pmids":["12958597","19267391"],"is_preprint":false},{"year":2022,"finding":"NHLRC1 knockdown in lung cancer cells reduced AKT phosphorylation at serine 473, attenuated cell proliferation, viability, migration, and invasion, and caused expression of pro-apoptotic AKT-repressed genes, identifying malin as a novel AKT activator in a cancer cell context.","method":"siRNA knockdown of NHLRC1 in lung cancer cell lines; measurement of AKT phosphorylation (pS473) by Western blot; cell proliferation, viability, migration, and invasion assays","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single knockdown approach, cancer cell context distinct from canonical neuronal function; no rescue or mechanistic follow-up","pmids":["36142605"],"is_preprint":false},{"year":2018,"finding":"In canine Lafora disease caused by EPM2B repeat expansion, polyglucosan bodies accumulate in neurons and are positive for laforin, hsp70, α/β-synuclein, ubiquitin, LC3, and p62, demonstrating that malin dysfunction leads to failure of ubiquitin-proteasome and autophagy pathway clearance of abnormal glycogen aggregates.","method":"Immunohistochemistry of polyglucosan bodies in canine Lafora disease brain tissue with markers for laforin, ubiquitin, autophagy receptors (LC3, p62), and chaperones","journal":"Veterinary pathology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — descriptive IHC in animal tissue; pathway inference from marker co-localization, no functional manipulation","pmids":["29444631"],"is_preprint":false},{"year":2025,"finding":"Intravenous delivery of rAAV2/9P31 carrying the EPM2B gene reversed neuropathological features, restored neuronal excitability and synaptic plasticity, and prevented Lafora body formation in Epm2b-/- mice, confirming that malin loss of function is the direct cause of these disease phenotypes and that EPM2B gene restoration is sufficient to rescue them.","method":"AAV-mediated gene delivery in Epm2b-/- mouse model; histopathology, electrophysiology, and behavioral assays","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo rescue with gene replacement in knockout model, multiple orthogonal readouts; single lab","pmids":["41169091"],"is_preprint":false},{"year":2026,"finding":"Overexpression of laforin (EPM2A) — but not malin (EPM2B) — paradoxically causes Lafora body formation independently of laforin and malin's enzymatic activities, and this occurs preferentially in dorsal root ganglia; in contrast, malin overexpression does not produce this toxic effect, indicating an asymmetry in the two proteins' safe overexpression profiles relevant to gene therapy.","method":"Intrathecal AAV9-based overexpression of EPM2A and EPM2B in mice; histopathology, neurophysiology; enzymatic activity mutants tested","journal":"Neurotherapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct comparison of EPM2A vs EPM2B overexpression with enzymatic mutants in vivo; single lab, multiple orthogonal methods","pmids":["41825228"],"is_preprint":false},{"year":2024,"finding":"In Epm2b-/- mice, loss of malin leads to dysregulation of glutamatergic receptor subunits (phospho-GluN2B, phospho-GluA2, GluK2) and increased GAT1 GABA transporter levels in hippocampus, with these changes occurring in activated microglia and reactive astrocytes rather than neurons, mediated via TNF and IL-6 inflammatory signaling pathways.","method":"Western blotting, immunofluorescence in Epm2b-/- mouse hippocampus; pathway analysis of TNF/IL-6 signaling","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, single lab, descriptive biochemical measurements in knockout tissue without functional rescue","pmids":[],"is_preprint":true}],"current_model":"NHLRC1 encodes malin, a RING finger E3 ubiquitin ligase that forms a complex with the laforin phosphatase at the endoplasmic reticulum; malin ubiquitinates and promotes degradation of laforin and the glycogen synthesis regulator R5/PTG, thereby controlling glycogen structural integrity, and loss-of-function mutations in either protein cause accumulation of toxic hyperphosphorylated polyglucosan (Lafora bodies), neuronal hyperexcitability, and the progressive myoclonic epilepsy of Lafora disease."},"narrative":{"mechanistic_narrative":"NHLRC1 encodes malin, a RING finger E3 ubiquitin ligase that operates with the laforin phosphatase at the endoplasmic reticulum to safeguard glycogen integrity, and whose loss causes the progressive myoclonic epilepsy of Lafora disease [PMID:12958597, PMID:19267391]. Malin and laforin colocalize at the ER and function as a complex regulating glycogen metabolism, such that loss of either protein leads to accumulation of insoluble polyglucosan (Lafora bodies) [PMID:12958597, PMID:19267391]. Mechanistically, malin's ubiquitin ligase activity degrades laforin itself and the glycogen-synthesis regulator R5/PTG, and disease-associated missense mutations abolish this turnover: the H187P mutation impairs laforin degradation [PMID:19322595], while C46Y, P69A, D146N, and L261P fail to downregulate R5/PTG and cause abnormal intracellular glycogen accumulation [PMID:21505799]. Other Lafora-causing mutations instead mislocalize malin to the nucleus or perinuclear aggregates, providing a second route to loss of function [PMID:18311786]. Malin loss-of-function is directly causative: AAV-mediated EPM2B restoration in Epm2b-/- mice reverses neuropathology, restores neuronal excitability and synaptic plasticity, and prevents Lafora body formation [PMID:41169091]. Beyond this glycogen-protective role, knockdown studies report malin as an activator of AKT signaling in a lung cancer context [PMID:36142605], though this lies outside the characterized neuronal pathway.","teleology":[{"year":2003,"claim":"Established the molecular identity of malin and placed it in a shared pathway with laforin, answering what the second Lafora disease gene encodes and where it acts.","evidence":"Positional cloning of NHLRC1/EPM2B identifying a RING finger + six NHL motif protein; ER colocalization with laforin by cell imaging","pmids":["12958597","19267391"],"confidence":"Medium","gaps":["E3 ligase activity inferred from domains, not reconstituted","physical interaction with laforin shown by colocalization rather than direct biochemistry","no substrate identified at this stage"]},{"year":2008,"claim":"Showed that some disease mutations act by mislocalizing malin away from its normal compartment, defining altered subcellular localization as one molecular basis of Lafora disease.","evidence":"Expression of six NHLRC1 missense mutants in cultured cells with localization analysis (nuclear targeting, perinuclear aggregation)","pmids":["18311786"],"confidence":"Medium","gaps":["no functional rescue linking mislocalization to loss of ligase activity","single lab","two of six mutants showed no localization change, leaving their mechanism unexplained"]},{"year":2009,"claim":"Provided direct functional evidence that malin acts as an E3 ligase toward laforin, converting the domain-based prediction into a demonstrated enzyme-substrate relationship.","evidence":"In vitro degradation assay showing H187P mutant fails to degrade laforin in cultured mammalian cells","pmids":["19322595"],"confidence":"Medium","gaps":["single mutant tested","ubiquitination per se not directly visualized","single lab"]},{"year":2011,"claim":"Identified R5/PTG as a second malin target and connected malin's ligase activity to glycogen metabolism, explaining how its loss produces glycogen overaccumulation.","evidence":"Expression of four NHLRC1 mutants in cells with R5/PTG protein levels and intracellular glycogen as orthogonal readouts","pmids":["21505799"],"confidence":"Medium","gaps":["direct ubiquitination of R5/PTG not shown in this assay","single lab","relative contribution of R5/PTG vs laforin turnover to disease unresolved"]},{"year":2018,"claim":"Linked malin dysfunction to failure of protein-quality-control clearance, showing that resulting aggregates engage both ubiquitin-proteasome and autophagy machinery.","evidence":"Immunohistochemistry of canine Lafora disease brain polyglucosan bodies positive for ubiquitin, LC3, p62, laforin, and chaperones","pmids":["29444631"],"confidence":"Low","gaps":["descriptive marker colocalization without functional manipulation","causality between malin loss and clearance failure inferred, not tested","animal-tissue observation only"]},{"year":2022,"claim":"Raised a non-neuronal role for malin as an AKT pathway activator, extending its proposed functions beyond glycogen regulation.","evidence":"siRNA knockdown of NHLRC1 in lung cancer lines with pS473-AKT Western blot and proliferation/migration/invasion assays","pmids":["36142605"],"confidence":"Low","gaps":["no rescue or mechanistic link to ligase activity","cancer context distinct from canonical neuronal function","single knockdown approach, single lab"]},{"year":2024,"claim":"Connected malin loss to glial inflammation and neurotransmitter-receptor dysregulation, addressing how glycogen pathology translates into neuronal hyperexcitability.","evidence":"Western blot and immunofluorescence in Epm2b-/- mouse hippocampus implicating glutamatergic/GABAergic subunit changes in glia via TNF/IL-6 signaling (preprint)","pmids":[],"confidence":"Low","gaps":["preprint, not peer-reviewed","descriptive measurements without functional rescue","causal direction between inflammation and receptor changes untested"]},{"year":2025,"claim":"Demonstrated that malin loss is the direct, sufficient cause of Lafora phenotypes and that gene restoration reverses them, establishing causality and therapeutic tractability.","evidence":"Intravenous rAAV2/9P31-EPM2B delivery in Epm2b-/- mice with histopathology, electrophysiology, and behavioral readouts","pmids":["41169091"],"confidence":"Medium","gaps":["single lab","durability and dosing window not defined","molecular requirement for ligase activity in the rescue not dissected"]},{"year":2026,"claim":"Revealed an asymmetry in overexpression safety between laforin and malin, informing gene-therapy design by showing only laforin excess is toxic and that toxicity is enzyme-independent.","evidence":"Intrathecal AAV9 overexpression of EPM2A vs EPM2B with enzymatic-activity mutants in mice; histopathology and neurophysiology","pmids":["41825228"],"confidence":"Medium","gaps":["mechanism of enzyme-independent laforin toxicity unresolved","single lab","DRG-preferential effect not mechanistically explained"]},{"year":null,"claim":"Whether the malin-laforin complex assembly, the direct ubiquitination chemistry, and the full substrate repertoire can be reconstituted biochemically remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["no in vitro reconstitution of malin ligase activity in the corpus","direct ubiquitin transfer to laforin/R5-PTG not visualized","structural basis of malin-laforin interaction uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,3]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,3]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2]}],"complexes":["laforin-malin complex"],"partners":["EPM2A","PPP1R3C"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6VVB1","full_name":"E3 ubiquitin-protein ligase NHLRC1","aliases":["Malin","NHL repeat-containing protein 1","RING-type E3 ubiquitin transferase NHLRC1"],"length_aa":395,"mass_kda":42.3,"function":"E3 ubiquitin-protein ligase. Together with the phosphatase EPM2A/laforin, appears to be involved in the clearance of toxic polyglucosan and protein aggregates via multiple pathways. In complex with EPM2A/laforin and HSP70, suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Ubiquitinates the glycogen-targeting protein phosphatase subunits PPP1R3C/PTG and PPP1R3D in a laforin-dependent manner and targets them for proteasome-dependent degradation, thus decreasing glycogen accumulation. Polyubiquitinates EPM2A/laforin and ubiquitinates AGL and targets them for proteasome-dependent degradation. Also promotes proteasome-independent protein degradation through the macroautophagy pathway","subcellular_location":"Endoplasmic reticulum; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q6VVB1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NHLRC1","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NHLRC1","total_profiled":1310},"omim":[{"mim_id":"620681","title":"MYOCLONIC EPILEPSY OF LAFORA 2; MELF2","url":"https://www.omim.org/entry/620681"},{"mim_id":"610860","title":"AMYLO-1,6-GLUCOSIDASE, 4-ALPHA-GLUCANOTRANSFERASE; AGL","url":"https://www.omim.org/entry/610860"},{"mim_id":"608072","title":"NHL REPEAT-CONTAINING PROTEIN 1; NHLRC1","url":"https://www.omim.org/entry/608072"},{"mim_id":"607566","title":"EPM2A GLUCAN PHOSPHATASE, LAFORIN; EPM2A","url":"https://www.omim.org/entry/607566"},{"mim_id":"606784","title":"GLYCOGEN SYNTHASE KINASE 3-ALPHA; GSK3A","url":"https://www.omim.org/entry/606784"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NHLRC1"},"hgnc":{"alias_symbol":["bA204B7.2","EPM2B"],"prev_symbol":[]},"alphafold":{"accession":"Q6VVB1","domains":[{"cath_id":"3.30.40.10","chopping":"24-96","consensus_level":"high","plddt":81.9371,"start":24,"end":96},{"cath_id":"2.120.10.30","chopping":"112-392","consensus_level":"high","plddt":90.8016,"start":112,"end":392}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6VVB1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6VVB1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6VVB1-F1-predicted_aligned_error_v6.png","plddt_mean":85.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NHLRC1","jax_strain_url":"https://www.jax.org/strain/search?query=NHLRC1"},"sequence":{"accession":"Q6VVB1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6VVB1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6VVB1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6VVB1"}},"corpus_meta":[{"pmid":"12958597","id":"PMC_12958597","title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12958597","citation_count":254,"is_preprint":false},{"pmid":"15781812","id":"PMC_15781812","title":"Lafora disease due to EPM2B mutations: a clinical and genetic study.","date":"2005","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15781812","citation_count":85,"is_preprint":false},{"pmid":"19267391","id":"PMC_19267391","title":"Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19267391","citation_count":80,"is_preprint":false},{"pmid":"12960212","id":"PMC_12960212","title":"Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22.","date":"2003","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12960212","citation_count":59,"is_preprint":false},{"pmid":"16190947","id":"PMC_16190947","title":"Late-onset and slow-progressing Lafora disease in four siblings with EPM2B mutation.","date":"2005","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/16190947","citation_count":54,"is_preprint":false},{"pmid":"16950819","id":"PMC_16950819","title":"Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora's progressive myoclonic epilepsy.","date":"2006","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16950819","citation_count":44,"is_preprint":false},{"pmid":"16134145","id":"PMC_16134145","title":"Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.","date":"2005","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16134145","citation_count":43,"is_preprint":false},{"pmid":"20738377","id":"PMC_20738377","title":"Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease.","date":"2010","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/20738377","citation_count":35,"is_preprint":false},{"pmid":"16021330","id":"PMC_16021330","title":"Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.","date":"2005","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16021330","citation_count":28,"is_preprint":false},{"pmid":"19322595","id":"PMC_19322595","title":"Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease.","date":"2009","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19322595","citation_count":23,"is_preprint":false},{"pmid":"27747878","id":"PMC_27747878","title":"NHLRC1 repeat expansion in two beagles with Lafora disease.","date":"2016","source":"The Journal of small animal practice","url":"https://pubmed.ncbi.nlm.nih.gov/27747878","citation_count":22,"is_preprint":false},{"pmid":"21505799","id":"PMC_21505799","title":"Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.","date":"2011","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/21505799","citation_count":18,"is_preprint":false},{"pmid":"29444631","id":"PMC_29444631","title":"Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.","date":"2018","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29444631","citation_count":18,"is_preprint":false},{"pmid":"18311786","id":"PMC_18311786","title":"Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin.","date":"2008","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/18311786","citation_count":15,"is_preprint":false},{"pmid":"28556688","id":"PMC_28556688","title":"Severe and rapidly-progressive Lafora disease associated with NHLRC1 mutation: a case report.","date":"2017","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28556688","citation_count":14,"is_preprint":false},{"pmid":"23317923","id":"PMC_23317923","title":"Lafora disease: severe phenotype associated with homozygous deletion of the NHLRC1 gene.","date":"2013","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23317923","citation_count":11,"is_preprint":false},{"pmid":"21555062","id":"PMC_21555062","title":"Rapidly progressive phenotype of Lafora disease associated with a novel NHLRC1 mutation.","date":"2011","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21555062","citation_count":10,"is_preprint":false},{"pmid":"30083360","id":"PMC_30083360","title":"A recurrent homozygous NHLRC1 variant in siblings with Lafora disease.","date":"2018","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/30083360","citation_count":9,"is_preprint":false},{"pmid":"22047982","id":"PMC_22047982","title":"Four novel and two recurrent NHLRC1 (EPM2B) and EPM2A gene mutations leading to Lafora disease in six Turkish families.","date":"2011","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/22047982","citation_count":8,"is_preprint":false},{"pmid":"34263924","id":"PMC_34263924","title":"NHLRC1 homozygous dodecamer expansion in a Newfoundland dog with Lafora disease.","date":"2021","source":"The Journal of small animal practice","url":"https://pubmed.ncbi.nlm.nih.gov/34263924","citation_count":7,"is_preprint":false},{"pmid":"41169091","id":"PMC_41169091","title":"Advances in gene therapy for Lafora disease: Intravenous recombinant adeno-associated virus-mediated delivery of EPM2A and EPM2B genes.","date":"2025","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41169091","citation_count":5,"is_preprint":false},{"pmid":"34117373","id":"PMC_34117373","title":"The rare rs769301934 variant in NHLRC1 is a common cause of Lafora disease in Turkey.","date":"2021","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34117373","citation_count":3,"is_preprint":false},{"pmid":"36142605","id":"PMC_36142605","title":"Identification of NHLRC1 as a Novel AKT Activator from a Lung Cancer Epigenome-Wide Association Study (EWAS).","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36142605","citation_count":3,"is_preprint":false},{"pmid":"41465357","id":"PMC_41465357","title":"Adeno-Associated Virus-Based Gene Therapy for Lafora Disease in Epm2b-Deficient Mice.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41465357","citation_count":2,"is_preprint":false},{"pmid":"35569391","id":"PMC_35569391","title":"Compound heterozygosity for novel variations of the NHLRC1 Gene in a family with Lafora disease.","date":"2022","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/35569391","citation_count":2,"is_preprint":false},{"pmid":"41825228","id":"PMC_41825228","title":"Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation.","date":"2026","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/41825228","citation_count":1,"is_preprint":false},{"pmid":"40217338","id":"PMC_40217338","title":"Identification of a pathogenic NHLRC1 variant in a consanguineous Pakistani family affected with severe and rapidly progressive Lafora disease.","date":"2025","source":"Acta epileptologica","url":"https://pubmed.ncbi.nlm.nih.gov/40217338","citation_count":1,"is_preprint":false},{"pmid":"41936809","id":"PMC_41936809","title":"Epm2bP71A and Epm2bD148N knock-in mouse models of Lafora disease exhibit distinct and pronounced neurological alterations.","date":"2026","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/41936809","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.23.650182","title":"Neuronal Hyperexcitability: A Key to Unravelling Hippocampal Synaptic Dysfunctions in Lafora Disease","date":"2025-04-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.23.650182","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.13.612874","title":"Glial alterations in the glutamatergic and GABAergic signaling pathways in a mouse model of Lafora disease, a severe form of progressive myoclonus epilepsy","date":"2024-09-15","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.13.612874","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14852,"output_tokens":2445,"usd":0.040615,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9638,"output_tokens":3006,"usd":0.06167,"stage2_stop_reason":"end_turn"},"total_usd":0.102285,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"NHLRC1 (EPM2B) encodes malin, a protein containing a RING finger domain and six NHL motifs, consistent with a putative E3 ubiquitin ligase. Malin and laforin (EPM2A) colocalize to the endoplasmic reticulum, suggesting they operate in a related pathway protecting against polyglucosan accumulation.\",\n      \"method\": \"Gene identification by positional cloning; colocalization by cell imaging\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — domain-based prediction of E3 ligase activity plus colocalization; replicated in subsequent studies but original evidence is domain inference + colocalization without in vitro reconstitution\",\n      \"pmids\": [\"12958597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NHLRC1 disease-associated missense mutations alter the subcellular localization of malin: three mutants (of six tested) targeted the nucleus, one formed perinuclear aggregates, and two showed no significant difference compared to wild-type malin, suggesting that altered subcellular localization of mutant malin is a molecular basis of Lafora disease.\",\n      \"method\": \"Expression of NHLRC1 missense mutants in cultured cells with subcellular localization analysis\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization experiment in mammalian cells with multiple mutants; single lab, no functional rescue shown\",\n      \"pmids\": [\"18311786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The NHLRC1 missense mutation H187P impairs malin's ability to degrade laforin in vitro, directly linking this mutation to loss of malin E3 ubiquitin ligase function toward its substrate laforin.\",\n      \"method\": \"In vitro degradation assay of laforin by mutant malin (H187P) in cultured mammalian cells\",\n      \"journal\": \"Neurogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct functional assay establishing laforin as a substrate of malin's ubiquitin ligase activity, single lab single mutant\",\n      \"pmids\": [\"19322595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Disease-associated NHLRC1 mutations (C46Y, P69A, D146N, L261P) cause failure to downregulate R5/PTG (a regulatory subunit of protein phosphatase 1 involved in glycogen synthesis) and lead to abnormal intracellular glycogen accumulation in cultured mammalian cells, demonstrating that malin regulates glycogen metabolism through control of R5/PTG levels.\",\n      \"method\": \"Expression of NHLRC1 mutants in cultured mammalian cells; measurement of R5/PTG protein levels and intracellular glycogen accumulation\",\n      \"journal\": \"Journal of molecular medicine (Berlin, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay with multiple mutants and two orthogonal readouts (R5/PTG levels + glycogen accumulation), single lab\",\n      \"pmids\": [\"21505799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Laforin and malin interact with each other and function as a complex that regulates glycogen metabolism; loss of either protein leads to polyglucosan (Lafora body) accumulation.\",\n      \"method\": \"Genetic and cell biological evidence from patient mutations and colocalization studies; complex function inferred from genetic epistasis\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Strong — supported by multiple independent studies documenting interaction and shared pathway, but original evidence is colocalization/genetic; interaction confirmed biochemically in subsequent work described in reviews\",\n      \"pmids\": [\"12958597\", \"19267391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NHLRC1 knockdown in lung cancer cells reduced AKT phosphorylation at serine 473, attenuated cell proliferation, viability, migration, and invasion, and caused expression of pro-apoptotic AKT-repressed genes, identifying malin as a novel AKT activator in a cancer cell context.\",\n      \"method\": \"siRNA knockdown of NHLRC1 in lung cancer cell lines; measurement of AKT phosphorylation (pS473) by Western blot; cell proliferation, viability, migration, and invasion assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single knockdown approach, cancer cell context distinct from canonical neuronal function; no rescue or mechanistic follow-up\",\n      \"pmids\": [\"36142605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In canine Lafora disease caused by EPM2B repeat expansion, polyglucosan bodies accumulate in neurons and are positive for laforin, hsp70, α/β-synuclein, ubiquitin, LC3, and p62, demonstrating that malin dysfunction leads to failure of ubiquitin-proteasome and autophagy pathway clearance of abnormal glycogen aggregates.\",\n      \"method\": \"Immunohistochemistry of polyglucosan bodies in canine Lafora disease brain tissue with markers for laforin, ubiquitin, autophagy receptors (LC3, p62), and chaperones\",\n      \"journal\": \"Veterinary pathology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — descriptive IHC in animal tissue; pathway inference from marker co-localization, no functional manipulation\",\n      \"pmids\": [\"29444631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Intravenous delivery of rAAV2/9P31 carrying the EPM2B gene reversed neuropathological features, restored neuronal excitability and synaptic plasticity, and prevented Lafora body formation in Epm2b-/- mice, confirming that malin loss of function is the direct cause of these disease phenotypes and that EPM2B gene restoration is sufficient to rescue them.\",\n      \"method\": \"AAV-mediated gene delivery in Epm2b-/- mouse model; histopathology, electrophysiology, and behavioral assays\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo rescue with gene replacement in knockout model, multiple orthogonal readouts; single lab\",\n      \"pmids\": [\"41169091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Overexpression of laforin (EPM2A) — but not malin (EPM2B) — paradoxically causes Lafora body formation independently of laforin and malin's enzymatic activities, and this occurs preferentially in dorsal root ganglia; in contrast, malin overexpression does not produce this toxic effect, indicating an asymmetry in the two proteins' safe overexpression profiles relevant to gene therapy.\",\n      \"method\": \"Intrathecal AAV9-based overexpression of EPM2A and EPM2B in mice; histopathology, neurophysiology; enzymatic activity mutants tested\",\n      \"journal\": \"Neurotherapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct comparison of EPM2A vs EPM2B overexpression with enzymatic mutants in vivo; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"41825228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In Epm2b-/- mice, loss of malin leads to dysregulation of glutamatergic receptor subunits (phospho-GluN2B, phospho-GluA2, GluK2) and increased GAT1 GABA transporter levels in hippocampus, with these changes occurring in activated microglia and reactive astrocytes rather than neurons, mediated via TNF and IL-6 inflammatory signaling pathways.\",\n      \"method\": \"Western blotting, immunofluorescence in Epm2b-/- mouse hippocampus; pathway analysis of TNF/IL-6 signaling\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, single lab, descriptive biochemical measurements in knockout tissue without functional rescue\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"NHLRC1 encodes malin, a RING finger E3 ubiquitin ligase that forms a complex with the laforin phosphatase at the endoplasmic reticulum; malin ubiquitinates and promotes degradation of laforin and the glycogen synthesis regulator R5/PTG, thereby controlling glycogen structural integrity, and loss-of-function mutations in either protein cause accumulation of toxic hyperphosphorylated polyglucosan (Lafora bodies), neuronal hyperexcitability, and the progressive myoclonic epilepsy of Lafora disease.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NHLRC1 encodes malin, a RING finger E3 ubiquitin ligase that operates with the laforin phosphatase at the endoplasmic reticulum to safeguard glycogen integrity, and whose loss causes the progressive myoclonic epilepsy of Lafora disease [#0, #4]. Malin and laforin colocalize at the ER and function as a complex regulating glycogen metabolism, such that loss of either protein leads to accumulation of insoluble polyglucosan (Lafora bodies) [#0, #4]. Mechanistically, malin's ubiquitin ligase activity degrades laforin itself and the glycogen-synthesis regulator R5/PTG, and disease-associated missense mutations abolish this turnover: the H187P mutation impairs laforin degradation [#2], while C46Y, P69A, D146N, and L261P fail to downregulate R5/PTG and cause abnormal intracellular glycogen accumulation [#3]. Other Lafora-causing mutations instead mislocalize malin to the nucleus or perinuclear aggregates, providing a second route to loss of function [#1]. Malin loss-of-function is directly causative: AAV-mediated EPM2B restoration in Epm2b-/- mice reverses neuropathology, restores neuronal excitability and synaptic plasticity, and prevents Lafora body formation [#7]. Beyond this glycogen-protective role, knockdown studies report malin as an activator of AKT signaling in a lung cancer context [#5], though this lies outside the characterized neuronal pathway.\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established the molecular identity of malin and placed it in a shared pathway with laforin, answering what the second Lafora disease gene encodes and where it acts.\",\n      \"evidence\": \"Positional cloning of NHLRC1/EPM2B identifying a RING finger + six NHL motif protein; ER colocalization with laforin by cell imaging\",\n      \"pmids\": [\"12958597\", \"19267391\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase activity inferred from domains, not reconstituted\", \"physical interaction with laforin shown by colocalization rather than direct biochemistry\", \"no substrate identified at this stage\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed that some disease mutations act by mislocalizing malin away from its normal compartment, defining altered subcellular localization as one molecular basis of Lafora disease.\",\n      \"evidence\": \"Expression of six NHLRC1 missense mutants in cultured cells with localization analysis (nuclear targeting, perinuclear aggregation)\",\n      \"pmids\": [\"18311786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"no functional rescue linking mislocalization to loss of ligase activity\", \"single lab\", \"two of six mutants showed no localization change, leaving their mechanism unexplained\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided direct functional evidence that malin acts as an E3 ligase toward laforin, converting the domain-based prediction into a demonstrated enzyme-substrate relationship.\",\n      \"evidence\": \"In vitro degradation assay showing H187P mutant fails to degrade laforin in cultured mammalian cells\",\n      \"pmids\": [\"19322595\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"single mutant tested\", \"ubiquitination per se not directly visualized\", \"single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified R5/PTG as a second malin target and connected malin's ligase activity to glycogen metabolism, explaining how its loss produces glycogen overaccumulation.\",\n      \"evidence\": \"Expression of four NHLRC1 mutants in cells with R5/PTG protein levels and intracellular glycogen as orthogonal readouts\",\n      \"pmids\": [\"21505799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"direct ubiquitination of R5/PTG not shown in this assay\", \"single lab\", \"relative contribution of R5/PTG vs laforin turnover to disease unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked malin dysfunction to failure of protein-quality-control clearance, showing that resulting aggregates engage both ubiquitin-proteasome and autophagy machinery.\",\n      \"evidence\": \"Immunohistochemistry of canine Lafora disease brain polyglucosan bodies positive for ubiquitin, LC3, p62, laforin, and chaperones\",\n      \"pmids\": [\"29444631\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"descriptive marker colocalization without functional manipulation\", \"causality between malin loss and clearance failure inferred, not tested\", \"animal-tissue observation only\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Raised a non-neuronal role for malin as an AKT pathway activator, extending its proposed functions beyond glycogen regulation.\",\n      \"evidence\": \"siRNA knockdown of NHLRC1 in lung cancer lines with pS473-AKT Western blot and proliferation/migration/invasion assays\",\n      \"pmids\": [\"36142605\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"no rescue or mechanistic link to ligase activity\", \"cancer context distinct from canonical neuronal function\", \"single knockdown approach, single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected malin loss to glial inflammation and neurotransmitter-receptor dysregulation, addressing how glycogen pathology translates into neuronal hyperexcitability.\",\n      \"evidence\": \"Western blot and immunofluorescence in Epm2b-/- mouse hippocampus implicating glutamatergic/GABAergic subunit changes in glia via TNF/IL-6 signaling (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"preprint, not peer-reviewed\", \"descriptive measurements without functional rescue\", \"causal direction between inflammation and receptor changes untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrated that malin loss is the direct, sufficient cause of Lafora phenotypes and that gene restoration reverses them, establishing causality and therapeutic tractability.\",\n      \"evidence\": \"Intravenous rAAV2/9P31-EPM2B delivery in Epm2b-/- mice with histopathology, electrophysiology, and behavioral readouts\",\n      \"pmids\": [\"41169091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"single lab\", \"durability and dosing window not defined\", \"molecular requirement for ligase activity in the rescue not dissected\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Revealed an asymmetry in overexpression safety between laforin and malin, informing gene-therapy design by showing only laforin excess is toxic and that toxicity is enzyme-independent.\",\n      \"evidence\": \"Intrathecal AAV9 overexpression of EPM2A vs EPM2B with enzymatic-activity mutants in mice; histopathology and neurophysiology\",\n      \"pmids\": [\"41825228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mechanism of enzyme-independent laforin toxicity unresolved\", \"single lab\", \"DRG-preferential effect not mechanistically explained\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether the malin-laforin complex assembly, the direct ubiquitination chemistry, and the full substrate repertoire can be reconstituted biochemically remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"no in vitro reconstitution of malin ligase activity in the corpus\", \"direct ubiquitin transfer to laforin/R5-PTG not visualized\", \"structural basis of malin-laforin interaction uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [\"laforin-malin complex\"],\n    \"partners\": [\"EPM2A\", \"PPP1R3C\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}